Treatment Sequences and Pharmacy Costs of 2 New Therapies for Metastatic Castration-Resistant Prostate Cancer
Lorie A. Ellis, PhD, Laurence Gozalo, PhD, Marie-Hélène Lafeuille, MA, Patrick Lefebvre, MA, Scott McKenzie, MD, Dominic Pilon, MA
Estimating the Costs of Therapy in Patients with Relapsed and/or Refractory Multiple Myeloma: A Model Framework
Anuja Roy, PhD, MBA, Jonathan K. Kish, PhD, MPH, Lisa Bloudek, PharmD, MS, David S. Siegel, MD, PhD, Sundar Jagannath, MD, Denise Globe, PhD, Emil T. Kuriakose, MD, Kristen Migliaccio-Walle, BS
Multiple myeloma is a malignant B-cell neoplasm of terminally differentiated plasma cells that accumulate in the bone marrow and frequently invade the adjacent bone, leading to bone destruction and marrow failure.
The Rationale for Comparing the Costs of Competing Treatment Options in Oncology
Sally Amanuel, MSc, MA, MBA, Paola Antonini, MD, PhD, Victoria Coutinho, MSc, PhD, Thomas Goss, PharmD, Zhihong Lai, PhD, Sotiris Rompas, Phd, Michael F. Murphy, MD, PhD
Adherence to Insulin Pen Therapy Is Associated with Reduction in Healthcare Costs Among Patients with Type 2 Diabetes Mellitus
Machaon M. Bonafede, PhD, MPH, Arthi Chandran, MS, MPH, Laurence J Hirsch, MD, Betsy J Lahue, MPH, Sonali Nigam, MPH, Rita Saltiel-Berzin, RN, MPH, CDE, CHES
Shelby Corman, PharmD, MS, BCPS, Xin Gao, PhD, Sizhu Liu, MS, Reema Mody, PhD,MBA, Haridarshan Patel, PharmD, Yin Wan, MS, BSPharm
Opioid-induced constipation (OIC) can be a debilitating side effect of opioid therapy and may result in increased medical costs. The published data on the economic burden of OIC among long-term opioid users are limited.
Opioid-Induced Constipation Associated with Considerable Economic Burden
Gabriela Dieguez, FSA, MAAA, Amy W. Law, PharmD, Richard Lynen, MD, James Trussell, PhD, Bruce Pyenson, FSA, MAAA
Pregnancy is associated with a significant cost for employers providing health insurance benefits to their employees. The latest study on the topic was published in 2002, estimating the unintended pregnancy rate for women covered by employer-sponsored insurance benefits to be approximately 29%.
A Call to Action to Address Burden of Unintended Pregnancies in Plans’ Benefit Design
Budgetary Impact of Adding Riociguat to a US Health Plan for the Treatment of Patients with Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension
Chakkarin Burudpakdee, PharmD, Anshul Shah, MS, Vijay N Joish, PhD, Christine H. Divers, PhD, Avin Yaldo, PhD
Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH), the 2 subtypes of pulmonary hypertension, are chronic, debilitating, and life-threatening conditions.
Is It Time for Risk-Sharing Contracts In Specialty Pharmacy?
Impact of the New ACC/AHA Guidelines on the Treatment of High Blood Cholesterol in a Managed Care Setting
Paul S Chan, MD, MSc, Heidi C. Lew, PharmD, Toros Cagla PhD, Brian K. Solow, MD, FAAFP, Karen M. Stockl, PharmD, Josephine N. Tran, PharmD, MS
In November 2013, the American College of Cardiology (ACC) and the American Heart Association (AHA) released together new clinical guidelines for the treatment of patients with high blood cholesterol. The 2013 guidelines provide a new paradigm for cholesterol management in the primary and secondary prevention of coronary artery disease (CAD)
Real-World Consequences of the 2013 ACC/AHA Cholesterol Guidelines for the Prevention of Cardiovascular Disease
Healthcare Costs Among Patients with Excessive Sleepiness Associated with Obstructive Sleep Apnea, Shift Work Disorder, or Narcolepsy
Rashad Carlton, PharmD, MSPH, Cathryn A. Carroll, PhD, Orsolya Lunacsek, PhD, Timothy S. Regan, BPharm, RPh, CPh
Excessive daytime sleepiness affects nearly 20% of the general population and is associated with many medical conditions, including shift work disorder (SWD), obstructive sleep apnea (OSA), and narcolepsy. Excessive sleepiness imposes a significant clinical, quality-of-life, safety, and economic burden on society.
Out-of-Pocket Cost of Therapy Can Affect Patients’ Excessive Sleepiness and Daytime Functioning
Lessons from the Leucovorin Shortages Between 2009 and 2012 in a Medicare Advantage Population: Where Do We Go from Here?
Three distinct shortages of the generic drug leucovorin, a reduced form of folic acid used in several chemotherapy regimens, were reported by the US Food and Drug Administration (FDA) between 2008 and 2014. Levoleucovorin, an alternative therapy to leucovorin, failed to demonstrate superiority over leucovorin in clinical trials and is substantially more expensive.
Drug Shortages Are Costly to Patients and to Payers
Page 4 of 12
Results 31 - 40 of 111
Results 31 - 40 of 111